Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer
International Journal of Molecular Sciences · 28.05.2024 · 25 (11) · 5876
DOI: 10.3390/ijms25115876 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.05.2024. Verfasst von Eun Hye Joo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Republic of Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer-Associated Fibroblasts, Erb-b2 Receptor Tyrosine Kinases, Cell Movement. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea, Ministry of Health and Welfare, Republic of Korea.
Abstract (Originalsprache)
Hormone receptor-positive and HER2-negative breast cancer (HR+/HER2-BC) is the most common type with a favorable prognosis under endocrine therapy. However, it still demonstrates unpredictable progression and recurrences influenced by high tumoral diversity and microenvironmental status. To address these heterogeneous molecular characteristics of HR+/HER2-BC, we aimed to simultaneously characterize its transcriptomic landscape and genetic architecture at the same resolution. Using advanced single-cell RNA and DNA sequencing techniques together, we defined four distinct tumor subtypes. Notably, the migratory tumor subtype was closely linked to genomic alterations of EGFR, related to the tumor-promoting behavior of IL6-positive inflammatory tumor-associated fibroblast, and contributing to poor prognosis. Our study comprehensively utilizes integrated analysis to uncover the complex dynamics of this breast cancer subtype, highlighting the pivotal role of the migratory tumor subtype in influencing surrounding cells. This sheds light on potential therapeutic targets by offering enhanced insights for HR+/HER2-BC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Republic of Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul 06355, Republic of Korea.
- Department of Breast Cancer Center, Samsung Medical Center, Seoul 06351, Republic of Korea.
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
- Planit Healthcare Inc., Seoul 06235, Republic of Korea.
- Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul 06355, Republic of Korea.
ORCID-Profile: Eun Hye Joo, Sangmin Kim, Taeseob Lee, Woong-Yang Park
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Ministry of Health and Welfare, Republic of Korea
- Ministry of Education, Republic of Korea
Zitieren
APA
Joo, E. H., Kim, S., Park, D., Lee, T., Park, W. Y., Han, K. Y., & Lee, J. E. (2024). Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer. International Journal of Molecular Sciences, 25(11), 5876. https://doi.org/10.3390/ijms25115876
Vancouver
Joo EH, Kim S, Park D, Lee T, Park WY, Han KY, et al. Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer. International Journal of Molecular Sciences. 2024;25(11):5876. doi:10.3390/ijms25115876
BibTeX
@article{Joo2024,
author = {Joo, Eun Hye and Kim, Sangmin and Park, Donghyun and Lee, Taeseob and Park, Woong-Yang and Han, Kyung Yeon and Lee, Jeong Eon},
title = {Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {11},
pages = {5876},
doi = {10.3390/ijms25115876}
}
EUVIMED